Elizabeth J Bell1, Pamela L Lutsey2, Saonli Basu3, Mary Cushman4, Susan R Heckbert5, Donald M Lloyd-Jones6, Aaron R Folsom2. 1. Division of Epidemiology & Community Health, University of Minnesota, Minneapolis. Electronic address: ebell@umn.edu. 2. Division of Epidemiology & Community Health, University of Minnesota, Minneapolis. 3. Division of Biostatistics, University of Minnesota, Minneapolis. 4. Division of Hematology/Oncology, Department of Medicine, University of Vermont, Burlington. 5. Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle. 6. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Abstract
BACKGROUND: Greater public awareness of venous thromboembolism may be an important next step for optimizing venous thromboembolism prevention and treatment. "Lifetime risk" is an easily interpretable way of presenting risk information. Therefore, we sought to calculate the lifetime risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism) using data from 2 large, prospective cohort studies: the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities (ARIC) study. METHODS: We followed participants aged 45-64 years in ARIC (n = 14,185) and ≥65 in CHS (n = 5414) at baseline visits (1987-1989 in ARIC, 1989-1990 and 1992-1993 in CHS) for incident venous thromboembolism (n = 728 in ARIC through 2011 and n = 172 in CHS through 2001). We estimated lifetime risks and 95% confidence intervals of incident venous thromboembolism using a modified Kaplan-Meier method, accounting for the competing risk of death from other causes. RESULTS: At age 45 years, the remaining lifetime risk of venous thromboembolism in ARIC was 8.1% (95% confidence interval, 7.1-8.7). High-risk groups were African Americans (11.5% lifetime risk), those with obesity (10.9%), heterozygous for the factor V Leiden (17.1%), or with sickle cell trait or disease (18.2%). Lifetime risk estimates differed by cohort; these differences were explained by differences in time period of venous thromboembolism ascertainment. CONCLUSIONS: At least 1 in 12 middle-aged adults will develop venous thromboembolism in their remaining lifetime. This estimate of lifetime risk may be useful to promote awareness of venous thromboembolism and guide decisions at both clinical and policy levels.
BACKGROUND: Greater public awareness of venous thromboembolism may be an important next step for optimizing venous thromboembolism prevention and treatment. "Lifetime risk" is an easily interpretable way of presenting risk information. Therefore, we sought to calculate the lifetime risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism) using data from 2 large, prospective cohort studies: the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities (ARIC) study. METHODS: We followed participants aged 45-64 years in ARIC (n = 14,185) and ≥65 in CHS (n = 5414) at baseline visits (1987-1989 in ARIC, 1989-1990 and 1992-1993 in CHS) for incident venous thromboembolism (n = 728 in ARIC through 2011 and n = 172 in CHS through 2001). We estimated lifetime risks and 95% confidence intervals of incident venous thromboembolism using a modified Kaplan-Meier method, accounting for the competing risk of death from other causes. RESULTS: At age 45 years, the remaining lifetime risk of venous thromboembolism in ARIC was 8.1% (95% confidence interval, 7.1-8.7). High-risk groups were African Americans (11.5% lifetime risk), those with obesity (10.9%), heterozygous for the factor V Leiden (17.1%), or with sickle cell trait or disease (18.2%). Lifetime risk estimates differed by cohort; these differences were explained by differences in time period of venous thromboembolism ascertainment. CONCLUSIONS: At least 1 in 12 middle-aged adults will develop venous thromboembolism in their remaining lifetime. This estimate of lifetime risk may be useful to promote awareness of venous thromboembolism and guide decisions at both clinical and policy levels.
Authors: A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman Journal: J Thromb Haemost Date: 2014-12-11 Impact factor: 5.824
Authors: Lucie Rychetnik; Penelope Hawe; Elizabeth Waters; Alexandra Barratt; Michael Frommer Journal: J Epidemiol Community Health Date: 2004-07 Impact factor: 3.710
Authors: Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Conrad Wittram; Margaret J Meehan; Elkan F Halpern; Jo-Anne O Shepard; Theresa C McLoud; James H Thrall Journal: J Thorac Imaging Date: 2004-07 Impact factor: 3.000
Authors: Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom Journal: Am J Med Date: 2004-07-01 Impact factor: 4.965
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison Journal: J Am Coll Cardiol Date: 2020-02-18 Impact factor: 24.094
Authors: Weihong Tang; Lu Yao; Nicholas S Roetker; Alvaro Alonso; Pamela L Lutsey; Carol C Steenson; Frank A Lederle; David W Hunter; Lindsay G S Bengtson; Weihua Guan; Emil Missov; Aaron R Folsom Journal: Arterioscler Thromb Vasc Biol Date: 2016-11-10 Impact factor: 8.311
Authors: Aaron R Folsom; Saonli Basu; Ching-Ping Hong; Susan R Heckbert; Pamela L Lutsey; Wayne D Rosamond; Mary Cushman Journal: Am J Med Date: 2019-04-04 Impact factor: 4.965
Authors: Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm Journal: J Thromb Thrombolysis Date: 2018-05 Impact factor: 2.300
Authors: Christina L Fanola; Faye L Norby; Amil M Shah; Patricia P Chang; Pamela L Lutsey; Wayne D Rosamond; Mary Cushman; Aaron R Folsom Journal: J Am Coll Cardiol Date: 2020-01-21 Impact factor: 24.094